25 related articles for article (PubMed ID: 10402722)
1. CA125 test result, test-to-diagnosis interval, and stage in ovarian cancer at diagnosis: a retrospective cohort study using electronic health records.
Funston G; Mounce LT; Price S; Rous B; Crosbie EJ; Hamilton W; Walter FM
Br J Gen Pract; 2021 Jun; 71(707):e465-e472. PubMed ID: 33875416
[TBL] [Abstract][Full Text] [Related]
2. ADAM17-A Potential Blood-Based Biomarker for Detection of Early-Stage Ovarian Cancer.
Rogmans C; Kuhlmann JD; Hugendieck G; Link T; Arnold N; Weimer JP; Flörkemeier I; Rambow AC; Lieb W; Maass N; Bauerschlag DO; Hedemann N
Cancers (Basel); 2021 Nov; 13(21):. PubMed ID: 34771725
[TBL] [Abstract][Full Text] [Related]
3. CA125 in ovarian cancer.
Scholler N; Urban N
Biomark Med; 2007 Dec; 1(4):513-23. PubMed ID: 20477371
[TBL] [Abstract][Full Text] [Related]
4. Development of a CA125-mesothelin cell adhesion assay as a screening tool for biologics discovery.
Scholler N; Garvik B; Hayden-Ledbetter M; Kline T; Urban N
Cancer Lett; 2007 Mar; 247(1):130-6. PubMed ID: 16677756
[TBL] [Abstract][Full Text] [Related]
5. Bead-based ELISA for validation of ovarian cancer early detection markers.
Scholler N; Crawford M; Sato A; Drescher CW; O'Briant KC; Kiviat N; Anderson GL; Urban N
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2117-24. PubMed ID: 16609024
[TBL] [Abstract][Full Text] [Related]
6. Ovarian cancer: the duplicity of CA125 measurement.
Karam AK; Karlan BY
Nat Rev Clin Oncol; 2010 Jun; 7(6):335-9. PubMed ID: 20368726
[TBL] [Abstract][Full Text] [Related]
7. Comparative analysis of CA125, tissue polypeptide specific antigen, and soluble interleukin-2 receptor alpha levels in sera, cyst, and ascitic fluids from patients with ovarian carcinoma.
Sedlaczek P; Frydecka I; Gabryś M; Van Dalen A; Einarsson R; Harłozińska A
Cancer; 2002 Nov; 95(9):1886-93. PubMed ID: 12404282
[TBL] [Abstract][Full Text] [Related]
8. The investigation of the factors affecting retroperitoneal lymph node metastasis in stage IIIC and IV epithelial ovarian cancer.
Yavuzcan A; Baloglu A; Cetinkaya B
Arch Gynecol Obstet; 2009 Dec; 280(6):939-44. PubMed ID: 19306011
[TBL] [Abstract][Full Text] [Related]
9. CA125 expression pattern, prognosis and correlation with serum CA125 in ovarian tumor patients. From The Danish "MALOVA" Ovarian Cancer Study.
Høgdall EV; Christensen L; Kjaer SK; Blaakaer J; Kjaerbye-Thygesen A; Gayther S; Jacobs IJ; Høgdall CK
Gynecol Oncol; 2007 Mar; 104(3):508-15. PubMed ID: 17113137
[TBL] [Abstract][Full Text] [Related]
10. Tissue polypeptide specific antigen and cancer associated serum antigen in the follow-up of ovarian cancer.
Sliutz G; Tempfer C; Kainz C; Mustafa G; Gitsch G; Koelbl H; Biegelmayer C
Anticancer Res; 1995; 15(3):1127-9. PubMed ID: 7645936
[TBL] [Abstract][Full Text] [Related]
11. [Epithelial ovarian cancer--preoperative assessment of Ca 125 levels as an independent prognostic factor].
Ivanov S; Ivanov S
Akush Ginekol (Sofiia); 2003; 42(3):16-9. PubMed ID: 12858485
[TBL] [Abstract][Full Text] [Related]
12. Preoperative tumor marker CA125 levels in relation to epithelial ovarian cancer stage.
Fures R; Buković D; Hodek B; Klarić B; Herman R; Grubisić G
Coll Antropol; 1999 Jun; 23(1):189-94. PubMed ID: 10402722
[TBL] [Abstract][Full Text] [Related]
13. [Value of CA 125 as a tumor marker in ovarian carcinoma].
Barrios CH; de P Guedes Neto E; Monteggia P; Fuhrmeister F; Basso A; Siqueira DP
Rev Assoc Med Bras (1992); 1995; 41(5):329-32. PubMed ID: 8731596
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
